McKesson Corporation (MCK) has been hightlighted as one of the best defensive healthcare value stock without a patent cliff. This evaluation is backed by multiple investors like billionaires Ray Dalio, Larry Robbins and Cliff Asness confirming it as a promising buy. Despite some underperformances compared to its competitors on certain days, McKesson outpaced the stock market gains on others. Over the last five years, the stock has proven lucrative with returns over 286%. It continues to attract investor attention for its resilient nature long-term, with shifts in market normalization post-COVID. Institutional investors, who control 88% of the company, have experienced significant gains despite losses of 11% in the last week. Recent divestment of Rexall and Well.ca businesses to Birch Hill Equity Partners and an earning miss in the first quarter of fiscal 2025 led to a drop in stock prices. However, McKesson also exhibited strong revenue growth and announced acquisition of a controlling interest in Florida Cancer Specialists & Research Institute’s Core Ventures. A cut in the price target by Deutsche Bank and mixed results in Q1 earnings have not deterred its reputation as a top value stock.
Mckesson Corporation MCK News Analytics from Fri, 19 Jan 2024 08:00:00 GMT to Sat, 12 Oct 2024 11:32:09 GMT -
Rating -1
- Innovation 2
- Information 5
- Rumor -3
